BR112012003916A2 - derivados de pirrolidinas como antagonistas de receptores nk3 - Google Patents

derivados de pirrolidinas como antagonistas de receptores nk3

Info

Publication number
BR112012003916A2
BR112012003916A2 BR112012003916A BR112012003916A BR112012003916A2 BR 112012003916 A2 BR112012003916 A2 BR 112012003916A2 BR 112012003916 A BR112012003916 A BR 112012003916A BR 112012003916 A BR112012003916 A BR 112012003916A BR 112012003916 A2 BR112012003916 A2 BR 112012003916A2
Authority
BR
Brazil
Prior art keywords
lower alkyl
halogen
receptor antagonists
hydrogen
pyrrolidine derivatives
Prior art date
Application number
BR112012003916A
Other languages
English (en)
Inventor
Angélique Patiny-Adam
Claus Riemer
Hasane Ratni
Henner Knust
Matthias Nettekoven
Philippe Jablonski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012003916A2 publication Critical patent/BR112012003916A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

''derivados de pirrolidinas como antagonistas de receptores nk3'' a presente invenção refere-se aos compostos de fórmula i: em que: r1 é hidrogênio ou alquila inferior; r2 é hidrogênio, alquila inferior, alquila inferios substituída por halogênio ou é halogênio ou cn e, se o for 2, podem ser qualquer um destes independentemente um do outro; ar1 é arila ou heteroarila; ar2 é arila ou heteroarila; r'/r'' sao, independentemente um do outro, hidrogênio, alquila inferior, alcóxi inferior, halogênio, c(o)-alquila inferior, ciano ou alquila inferior ou substituída por halogênio;m é 0, 1 ou 2, quando n for 0; ou m é 0 ou 1 quando n for 1; n é 0 ou 1; 0 é 1 ou 2; ou a sais farmaceuticamente ativos, misturas racêmicas, enantiômeros, isômeros ópticos a formas tautoméricas dos mesmos. foi constado que os presentes compostos são antagonistas de receptoresnk-3 de alto potencial para o tratamento de depressão, dor, psicoses, doença de parkinson, esquizofrenia, ansiedade e de transtorno do défcit de atenção e hiperatividade (adhd).
BR112012003916A 2009-08-25 2010-08-20 derivados de pirrolidinas como antagonistas de receptores nk3 BR112012003916A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09168630 2009-08-25
PCT/EP2010/062141 WO2011023626A1 (en) 2009-08-25 2010-08-20 Pyrrolidine derivatives as nk3 receptor antagonists

Publications (1)

Publication Number Publication Date
BR112012003916A2 true BR112012003916A2 (pt) 2016-03-29

Family

ID=42727567

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012003916A BR112012003916A2 (pt) 2009-08-25 2010-08-20 derivados de pirrolidinas como antagonistas de receptores nk3

Country Status (13)

Country Link
US (1) US8394834B2 (pt)
EP (1) EP2470524B1 (pt)
JP (1) JP5513619B2 (pt)
KR (1) KR101514505B1 (pt)
CN (1) CN102482259B (pt)
AU (1) AU2010288666B2 (pt)
BR (1) BR112012003916A2 (pt)
CA (1) CA2767770C (pt)
ES (1) ES2430357T3 (pt)
IL (1) IL217759A (pt)
MX (1) MX2012001799A (pt)
SG (1) SG178857A1 (pt)
WO (1) WO2011023626A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040663A1 (en) * 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Pyrrolidine n-benzyl derivatives
EP2577849B1 (en) 2010-05-28 2020-12-16 Seabased AB Stator frame for a submerged linear generator
KR20150021036A (ko) 2012-06-14 2015-02-27 다이이찌 산쿄 가부시키가이샤 피페리디닐피라졸로피리딘 유도체
EA025166B1 (ru) * 2012-08-21 2016-11-30 Ф. Хоффманн-Ля Рош Аг Производные пиридина
CA3052479A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CA3052480A1 (en) * 2017-02-17 2018-08-23 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1859914A (zh) * 2003-09-30 2006-11-08 默克公司 苯基吡咯烷醚速激肽受体拮抗剂
US7138423B2 (en) * 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists
MX2010001080A (es) 2007-08-07 2010-03-01 Hoffmann La Roche Pirrolidin-aril-eteres como antagonistas de receptor de nk3.
WO2009024502A1 (en) 2007-08-22 2009-02-26 F. Hoffmann-La Roche Ag Pyrrolidine aryl-ether as nk3 receptor antagonists
US8063075B2 (en) 2008-06-10 2011-11-22 Hoffmann-La Roche Inc. Pyrrolidine ether derivatives as NK3 receptor antagonists

Also Published As

Publication number Publication date
AU2010288666A1 (en) 2012-02-02
ES2430357T3 (es) 2013-11-20
KR20120059580A (ko) 2012-06-08
CN102482259B (zh) 2014-09-17
CA2767770A1 (en) 2011-03-03
IL217759A (en) 2015-09-24
MX2012001799A (es) 2012-03-16
EP2470524B1 (en) 2013-07-24
IL217759A0 (en) 2012-03-29
JP5513619B2 (ja) 2014-06-04
KR101514505B1 (ko) 2015-04-22
AU2010288666B2 (en) 2013-11-14
WO2011023626A1 (en) 2011-03-03
CA2767770C (en) 2017-06-13
SG178857A1 (en) 2012-04-27
US8394834B2 (en) 2013-03-12
CN102482259A (zh) 2012-05-30
US20110053948A1 (en) 2011-03-03
EP2470524A1 (en) 2012-07-04
JP2013503126A (ja) 2013-01-31

Similar Documents

Publication Publication Date Title
BR112012003916A2 (pt) derivados de pirrolidinas como antagonistas de receptores nk3
ATE486058T1 (de) Prolinamidderivate als nk3-antagonisten
PE20140934A1 (es) Derivados de pirazol
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
CY1111308T1 (el) Παρασκευη εσλικαρβαζεπινης και σχετικων ενωσεων με ασυμμετρη υδρογονωση
EA201391341A1 (ru) Производные гетероциклических аминов
AR080056A1 (es) Derivados de ciclohexil-amida como antagonistas de los receptores de crf
UA109525C2 (xx) Алкіламідна сполука і її застосування
MX2010001774A (es) Pirrolidin aril-eteres como antagonistas de receptores de nk3.
BRPI0810402A2 (pt) Derivados de pirrolidina como antagonistas duais dos receptores nk1/nk3
CL2013003485A1 (es) Compuestos derivados de benzamida sustituida como moduladores de receptores asociados con las aminas traza (taar1); composición farmacéutica; procedimiento de preparación; y uso en el tratamiento de depresión, psicosis, enfermedad de parkinson, ansiedad, trastorno de hiperactividad (adhd) y diabetes.
BR112014015832A8 (pt) derivados heterocíclicos como receptores associados com aminas vistigiais (taars)
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
EA200970911A1 (ru) Хинолины и их терапевтическое применение
MX2011008850A (es) Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3).
BR112013000253A2 (pt) derivados de (3-metilpirrolidin-3-il) metil piridinil éter e seu uso como antagonistas do receptor nk-3
BR112012014576A2 (pt) derivados de pirrolidina como antagonistas do receptor nk-3
PE20141168A1 (es) Derivados de pirazolidin-3-ona
CY1118595T1 (el) Αρυλοαιθινυλο πυριμιδινες
MX2011008178A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).
EA201001889A1 (ru) Производные дибензотиазепина и их применение
PE20081893A1 (es) Subtipo de amidas selectivas de diazabicicloalcanos
MX2011007506A (es) Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3).
MX2013007411A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).
ATE546455T1 (de) Spiropiperidinderivate als nk3-antagonisten

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2529 DE 25-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.